The vaccine research and development (R&D) ecosystem has yielded life-saving products for decades by leveraging innovation, collaboration, and partnership; but the rapid development of COVID-19 vaccines illustrated that even more is possible when the right circumstances are in place to catalyze progress.

Vaccine Science and Policy Experts Call for Transformation of Vaccine R&D Enterprise

In a new report, “Powering Vaccine R&D: Opportunities for Transformation,” the Sabin-Aspen Vaccine Science & Policy Group uses lessons learned from the rapid development of COVID-19 vaccines to explore opportunities to overhaul vaccine R&D practices to better prepare for the next pandemic, to make strides against diseases currently without vaccines, and to establish next-generation vaccines that offer meaningful improvements.

Powering Vaccine R&D: Opportunities for Transformation

Restructuring R&D to produce essential vaccines for infectious diseases we already recognize, and for those yet to emerge, is imperative. Powering Vaccine R&D: Opportunities for Transformation is a new report published by the Sabin-Aspen Vaccine Science & Policy Group that examines the core components of the vaccine ecosystem and finds opportunities to transform and accelerate the development of vaccines.

This blog post is part of Sabin’s Vaccine IQ: Intro to Vaccine Research & Development series, in which experts from Sabin’s Vaccine R&D team give an introduction to how vaccines are made, explaining the stages of research, development and testing vaccine candidates must go th

Dr. Regina Rabinovich Succeeds Dr. Axel Hoos as Sabin Vaccine Institute Board Chair, Drs. Norman Baylor and JoAnn Suzich Join the Board

The Sabin Vaccine Institute (Sabin) is pleased to announce the Board of Trustees has unanimously elected Regina Rabinovich, MD, MPH, as board chair and elected two new trustees, Dr. Norman Baylor and Dr. JoAnn Suzich, to strengthen the organization’s leadership in global immunization and vaccine research and development.

This blog post is part of Sabin’s Vaccine IQ: Intro to Vaccine Research & Development series, in which experts from Sabin’s Vaccine R&D team give an introduction to how vaccines are made, explaining the stages of research, development and testing vaccine candidates must go th

This blog post is part of Sabin’s Pivoting in a Pandemic series, which captures stories of extraordinary leaders who are adapting to advance research and public health in the midst of the COVID-19 pandemic.

This blog post is part of Sabin’s Vaccine IQ: Intro to Vaccine Research & Development series, in which experts from Sabin’s Vaccine R&D team give an introduction to how vaccines are made, explaining the stages of research, development and testing vaccine candidates must go th

Statement Regarding Industry Funding

Approved by Board of Trustees May 2020

Sabin partners with multiple organizations in the vaccine and immunization community, including the pharmaceutical and biotechnology industry (industry), to implement its Global Immunization and Research & Development Programs. Sabin operates independently from industry and controls and restricts programs and activities that may be supported by industry as outlined below. Furthermore, this policy is reviewed annually by Sabin's Board of Trustees.

Pages

Subscribe to RSS - Research & Development